Why the study?
Does AT1R blocking in bone marrow cells prevent the progression of atherosclerosis?
Does AT1R blocking in bone marrow cells prevent the progression of atherosclerosis?
Targeting the local bone marrow renin-angiotensin system via AT1R blockade may offer a novel therapeutic strategy for preventing atherosclerosis.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for bone marrow AT1R blockade in atherosclerosis; prospective trials needed before clinical consideration.
Local hematopoietic bone marrow (BM) renin-angiotensin system (RAS) affects the growth, production, proliferation differentiation, and function of hematopoietic cells. Angiotensin II (Ang II), the dominant effector peptide of the RAS, regulates cellular growth in a wide variety of tissues in pathobiological states. RAS, especially Ang II and Ang II type 1 receptor (AT1R), has considerable proinflammatory and proatherogenic effects on the vessel wall, causing progression of atherosclerosis. Recent investigations, by analyzing several BM chimeric mice whose BM cells were positive or negative for AT1R, disclosed that AT1R in BM cells participates in the pathogenesis of atherosclerosis. Therefore, AT1R blocking not only in vascular cells but also in the BM could be an important therapeutic approach to prevent atherosclerosis. The aim of this paper is to review the function of local BM RAS in the pathogenesis of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Beyazıt et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: